Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27926430 | 0.76 | ACHE (0.31) | ACHE | |
| SCHEMBL10901594 | 0.76 | ACHE (0.36) | ACHECA9CYP3A4MAPTCA12 | |
| SCHEMBL2154014 | 0.76 | ACHE (0.41) | ACHECA9CYP3A4MAPTPTGS2 | |
| SCHEMBL8037350 | 0.74 | KDM4E (0.31) | KDM4EHSD17B10 | |
| SCHEMBL311915 | 0.74 | ACHE (0.34) | ACHECA9CYP3A4MAPTPTGS2 | |
| SCHEMBL1466344 | 0.74 | MAPT (0.43) | ACHECA9CYP3A4MAPTPTGS2 | |
| SCHEMBL312248 | 0.74 | ACHE (0.34) | ACHECA9CYP3A4MAPTPTGS2 | |
| SCHEMBL313310 | 0.74 | ACHE (0.34) | ACHECA9CYP3A4MAPTPTGS2 | |
| SCHEMBL312860 | 0.74 | ACHE (0.34) | ACHECA9CYP3A4MAPTPTGS2 | |
| SCHEMBL4963852 | 0.74 | MAPT (0.33) | MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975259-B2 | Compositions and methods for inhibiting G protein signaling | UNIVERSITY OF ROCHESTER (US) | 2015-03-10 | — | — | US | claimed |
| EP-2190466-A2 | TISSUE-NONSPECIFIC ALKALINE PHOSPHATASE (TNAP) ACTIVATORS AND USES THEREOF | Burnham Institute for Medical Research (US) | 2010-06-02 | — | — | EP | claimed |
| US-20100130505-A1 | COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING | UNIVERSITY OF ROCHESTER (US) | 2010-05-27 | — | — | US | claimed |
| EP-2147310-A2 | COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING | University of Rochester (US) | 2010-01-27 | — | — | EP | claimed |
| WO-2009020677-A9 | COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING | UNIV ROCHESTER (US) | 2009-04-16 | — | — | WO | claimed |
| WO-2009042294-A2 | TISSUE-NONSPECIFIC ALKALINE PHOSPHATASE (TNAP) ACTIVATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-04-02 | — | — | WO | claimed |
| US-20090053192-A1 | TISSUE-NONSPECIFIC ALKALINE PHOSPHATASE (TNAP) ACTIVATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-26 | — | — | US | claimed |
| WO-2009020677-A2 | COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING | UNIVERSITY OF ROCHESTER (US) | 2009-02-12 | — | — | WO | claimed |
| CN-1612856-A | 1,3-diarylprop-2-en-1-ones, compositions containing same and use thereof | AVENTIS PHARMA SA (FR) | 2005-05-04 | — | — | CN | claimed |
| EP-1453790-A2 | 1,3-DIARYLPROP-2-EN-1-ONES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | Aventis Pharma S.A. (FR) | 2004-09-08 | — | — | EP | claimed |
| US-20040147584-A2 | 1,3-DIARYLPROP-2-EN-1-ONES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2004-07-29 | — | — | US | claimed |
| US-20030153611-A1 | 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof | AVENTIS PHARMA S.A. | 2003-08-14 | — | — | US | claimed |
| WO-2003048106-A2 | 1,3-DIARYLPROP-2-EN-1-ONES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2003-06-12 | — | — | WO | claimed |
| EP-4181241-A1 | H20 - BASED ELECTROCHEMICAL HYDROGEN - CATALYST POWER SYSTEM | Brilliant Light Power, Inc. (US) | 2023-05-17 | — | — | EP | disclosed |
| US-20210313606-A1 | H2O-BASED ELECTROCHEMICAL HYDROGEN-CATALYST POWER SYSTEM | BRILLIANT LIGHT POWER, INC. (US) | 2021-10-07 | — | — | US | disclosed |
| EP-3189024-B9 | FULLERENE MIXTURES FOR USE IN ORGANIC ELECTRONIC DEVICES | RAYNERGY TEK INC (TW) | 2021-06-09 | — | — | EP | disclosed |
| EP-0292431-A2 | Improved gas diffusion electrode | ELTECH SYSTEMS CORPORATION (US) | 1988-11-23 | — | — | EP | disclosed |
| CN-88101588-A | Preparation 1, the method for 4-disubstituted piperazines compounds | — | 1988-11-23 | — | — | CN | disclosed |
| EP-0284359-A1 | 1,4-Disubstituted piperazine compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1988-09-28 | — | — | EP | disclosed |
| US-4261913-A | FOR TREATING FILLERS TO INCREASE FILLER LOADING OF POLYMERS | KENRICH PETROCHEMICALS, INC. (US) | 1981-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147584-A2 | 1,3-DIARYLPROP-2-EN-1-ONES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | MCL1, ENPP1, MYC | ACHE 3810/4885CA9 4466/4885CYP3A4 802/4885 |
| US-20100130505-A1 | COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING | GNAI1, GNAI3, GNAI2 | ACHE 1991/4885CA9 3963/4885CYP3A4 4860/4885 |
| US-20090053192-A1 | TISSUE-NONSPECIFIC ALKALINE PHOSPHATASE (TNAP) ACTIVATORS AND USES THEREOF | ALPL, ALPP, ACP3 | ACHE 777/4885CA9 576/4885CYP3A4 4763/4885 |
| US-20030153611-A1 | 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof | MCL1, ENPP1, MYC | ACHE 3810/4885CA9 4466/4885CYP3A4 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.